logo
Share SHARE
FONT-SIZE Plus   Neg

Merck KgaA Inks License Agreement With Symphogen On Sym004 - Update

Merck KGaA (MKGAY.PK) said Thursday that an exclusive worldwide license agreement was signed with Copenhagen, Denmark-based Symphogen A/S for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor or EGFR.

As per the agreement, Merck will gain exclusive worldwide rights to develop and commercialize Sym004 and will pay Symphogen 20 million euros upfront. Merck will also make payments to Symphogen for clinical development, regulatory and sales performance milestones. Symphogen will also be eligible for potential royalties on net worldwide sales.

Sym004 is comprised of two antibodies that are designed to block ligand binding, receptor activation and downstream signaling. They are also thought to elicit removal of the EGFR receptors from the cancer cell surface by inducing EGFR internalization and degradation.

Sym004 is currently being evaluated in a Phase I/II trial for the treatment of patients with advanced KRAS wild-type metastatic colorectal cancer or mCRC, who have previously progressed on treatment with standard chemotherapy and a marketed anti-EGFR monoclonal antibody.

Additionally, a single-arm, open-label Phase II trial in patients with squamous cell carcinoma of the head and neck, or SCCHN, who have failed anti-EGFR-based therapy is currently in progress.

Dr. Susan Jane Herbert, Head of Global Business Development and Strategy for the Merck Serono division, said, "Sym004 further strengthens our early development pipeline by adding a product that is thought to act via a proposed synergistic mechanism of action not previously studied, but more specifically, it has the potential to become a key asset complementing our already highly successful Erbitux franchise."

The stock closed up 0.79 percent in Frankfurt on Wednesday at 91.65 euros.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Private equity firm Sycamore Partners has won the bankruptcy auction for the e-commerce business and intellectual property of U.S. women's apparel retailer The Limited with a bid of $26.8 million, Reuters reported, citing people familiar with the matter. A U.S. bankruptcy court judge must now approve the sale to Sycamore Partners. French telecommunications operator Orange SA reported Thursday higher net profit in its fiscal year 2016 mainly on income from discontinued operations. Operating income, meanwhile, declined, despite increased revenues. For fiscal 2017, the company projects higher adjusted EBITDA, a key earnings metric. Fast-food giant McDonald's plans to offer big discounts on its sodas and coffee, aiming to meet the declining customer visits, Bloomberg reported Wednesday. The company is likely to offer $1 sodas of any size for a limited time starting in April across the U.S. Further, McCafe specialty drinks, which normally range from $2.69 and $4, will be sold for $2 for a limited time.
comments powered by Disqus
Follow RTT